Idexx Laboratories Inc (IDXX) Financials
Key financial figures for Idexx Laboratories Inc (Q2 2026).
IDEXX Q2 2026 revenue grew 10% to $1.217 billion, GAAP EPS rose 17% to $4.27, and management raised full-year 2026 guidance to $4.700-$4.745 billion revenue and $14.69-$14.94 EPS. Revenue reached $1,216.6 million, up 10% as reported and 9% organic, beating the Street estimate of $1.201 billion GAAP diluted EPS of $4.27 (+17% YoY) beat consensus of $3.96; comparable EPS was $4.07 CAG segment revenue rose 9% to $1,118.2 million, with CAG Diagnostics recurring revenue up 11% reported (10% organic) Rapid assay diagnostics revenue grew to $101.6 million from $84.9 million in Q1 2026 Water segment revenue climbed 15% to $59 million on strong US and European demand Free cash flow was $322.5 million on operating cash flow of $347.2 million for the quarter On the outlook: IDEXX raised full-year 2026 guidance to revenue of $4.700-$4.745 billion (from $4.675-$4.760 billion), GAAP EPS of $14.69-$14.94 (from $14.45-$14.90), and organic revenue growth of 8.5%-9.7% (from 7.7%-9.7%), citing stronger CAG Diagnostics recurring revenue and margin performance. Figures are for Q2 2026, as IDEXX Laboratories, Inc. reported them.
- Revenue
- $1.2B
- Net Income
- $338M
- EPS
- $4.29
- Total Assets
- $3.4B
- Operating Cash Flow
- $347M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $1.2B | $338M | $4.19 | 34.98% | $323M |
| Q1 FY2026 | $1.1B | $278M | $3.45 | 31.78% | $234M |
| Q4 FY2025 | $1.1B | $248M | $3.08 | 28.94% | $323M |
| Q3 FY2025 | $1.1B | $275M | $3.40 | 32.11% | $371M |
| Q2 FY2025 | $1.1B | $294M | $3.63 | 33.62% | $152M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $4.3B | $1.1B | $13.08 | 31.6% | $1.1B |
| FY2024 | $3.9B | $888M | $10.67 | 28.95% | $798M |
| FY2023 | $3.7B | $845M | $10.06 | 29.97% | $773M |
Frequently asked questions
What was IDEXX Laboratories, Inc.'s revenue last quarter?
IDEXX Laboratories, Inc. reported revenue of $1.22 billion for Q2 FY2026, up 9.7% from the same period a year earlier.
Is IDEXX Laboratories, Inc. profitable?
Yes. IDEXX Laboratories, Inc. reported net income of $338.4 million for Q2 FY2026, a net margin of 27.82% on revenue.
How has IDEXX Laboratories, Inc.'s margin trended?
Operating margin was 34.98% in Q2 FY2026, compared with 33.62% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did IDEXX Laboratories, Inc. generate?
IDEXX Laboratories, Inc. generated free cash flow of $322.5 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Idexx Laboratories Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.